The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive ...
Labcorp added to its suite of tests designed to detect cancer recurrence much earlier than traditional imaging.
Although 76% respondents reported encountering medical misinformation, that exposure was not significantly associated with clinically significant fear of cancer recurrence or self-reported treatment ...
Baseline ctDNA presence linked to larger tumors and higher residual cancer burden scores in HR-positive early breast cancer patients. Persistent ctDNA post-neoadjuvant endocrine therapy associated ...
Despite the prevalence of cancer misinformation, exposure to it is not associated with greater fear of cancer recurrence or ...
MCM2 expression in locally advanced hormone receptor–positive HER2 negative (HR+/HER2-) early breast cancer receiving neoadjuvant chemotherapy. Data were expressed as Area Under the Curve (AUC) and 95 ...
AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has received Breakthrough Therapy Designation from the U.S. Food and Drug ...
Although three-fourths (76%) of breast cancer patients are exposed to cancer misinformation, perpetuating fear in 38%, it did ...
Studying a person's genetic makeup can predict if they will go on to develop invasive breast cancer after abnormal cells have been found in their breast tissue. For the first time, researchers at King ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback